Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Program.

Silvio DaneseAxel DignassKatsuyoshi Matsuoka Marc FerranteMillie LongIsabel RedondoRichard MosesSebastian MaierTheresa Hunter GibbleNathan MorrisCatherine MilchMaria T Abreu

Published in: Journal of Crohn's & colitis (2024)

Mirikizumab demonstrated efficacy in achieving and sustaining symptom control and comprehensive symptom control over 52 weeks. [NCT03518086; NCT03524092].

Keyphrases

ulcerative colitis
patient reported